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Serum neopterin levels in relation to mild
and severe COVID-19
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Abstract
Background: The COVID-19 pandemic, caused by the coronavirus SARS-CoV-2, is rapidly spreading worldwide. There is
limited information about prognostic markers that could help clinicians to identify COVID-19 patients with a poor
prognosis. Serum levels of the immune activation marker neopterin has shown to be of prognostic value in patients with
SARS. The aim of this study was to investigate whether serum neopterin is associated with the severity of COVID-19.
Methods: We included 34 patients with confirmed COVID-19 between March 3 and March 30, 2020. Fifteen patients had
mild disease and did not require hospitalization, whereas 19 patients developed severe COVID-19 requiring intensive care.
Concentrations of serum neopterin, tryptophan, and kynurenine were measured at and repeatedly after inclusion.
Results: We found a more than two-fold higher mean concentration of neopterin in severely ill patients (mean value
42.0 nmol/L (SD 18.2)) compared to patients with mild symptoms (16.9 nmol/L (SD 11.0)). All of the severe cases had
elevated neopterin concentrations (> 9.1 nmol/L) at the initial sampling with values ranging from 17.2 to 86.7 nmol/L.
In comparison, 10 of 15 patients with mild disease had neopterin levels above 9.1 nmol/L, with concentrations in the
range from 4.9 to 31.6 nmol/L. Neopterin levels gradually decreased during the course of COVID-19, but severe cases
maintained elevated levels for a longer period. Moreover, lower levels of tryptophan and higher levels of kynurenine,
indicating an increased tryptophan catabolism, were seen in the group with severe cases.
Conclusions: In conclusion, we found that serum neopterin levels are associated with the severity of COVID-19. Our
findings suggest that neopterin could be used as a prognostic marker, but further studies are needed to elucidate how
it can be used in the clinic.
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Introduction
The COVID-19 pandemic, caused by the coronavirus
SARS-CoV-2, is rapidly spreading worldwide [1]. Most
patients have mild symptoms from the upper respiratory
tract, whereas a minor but not negligible proportion suf-
fers from a severe form of the disease, which in some
cases require intensive care [2]. There is limited
information about prognostic markers that could help
clinicians to identify COVID-19 patients with a poor
prognosis. During the outbreak of the severe acute re-
spiratory syndrome (SARS) in 2002–2003, caused by the
similar coronavirus SARS-CoV, levels of the immune ac-
tivation marker neopterin were found to predict the
course of disease [3].
Neopterin (6-(D-erythro-1′, 2′, 3′-trihydroxypropyl)-
pterin) is a well-established immune activation marker
with elevated concentrations seen in many inflammatory
states including infections, autoimmune disorders, and
cancer [4]. In acute viral infections such as hepatitis [5],
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Cytomegalovirus disease [6], Rubella [7], and dengue
fever [8], serum neopterin levels correlate with the activity
of the disease, and can be detected before antibody produc-
tion [4]. The elevation of neopterin originates mainly from
the increased synthesis by human monocyte-derived mac-
rophages, whereby interferon-gamma (IFN-y) is the most
central activating cytokine [9]. IFN-y also promotes the
conversion of the essential amino acid L-tryptophan (TRP)
to N-formylkynurenine, which is rapidly converted into the
more stable kynurenine (KYN), by induction of the anti-
proliferative and immunoregulatory enzyme indoleamine 2,
3-dioxygenase (IDO). The first step of the TRP breakdown
is the rate-limiting step in the TRP catabolic route along
the KYN axis, and the KYN to TRP ratio can be used as a
measure of the IDO enzyme activity [10]. Taken together,
IFN-y mediated immune response to viral infections may
lead to elevated neopterin levels, as well as increased TRP
degradation and elevated KYN to TRP ratio [4, 11].
In patients with SARS, elevated levels of neopterin
were detected already at the day of symptom onset, and
rose to a maximum level at day 3 [3]. Moreover, patients
with higher levels of neopterin at an early stage suffered
from a severer course of disease, including higher and
longer period of fever, more severe dyspnea, longer
hospitalization, and more complications [3]. Considering
these findings and the similarity of the coronaviruses,
neopterin may be a useful prognostic marker for the
course of COVID-19. The aim of this study was to inves-
tigate whether serum neopterin levels in COVID-19 pa-
tients are associated with the severity of disease.
Methods
Participants
We included 34 patients with COVID-19, who were ad-
mitted to the Department of Infectious Diseases at the
Sahlgrenska University Hospital, Gothenburg, Sweden.
All cases were confirmed with reverse transcriptase poly-
merase chain reaction (RT-PCR) from nasopharyngeal
and throat aspirates. Fifteen patients had mild disease
and did not require hospitalization, whereas 19 patients
developed severe COVID-19 that in most cases required
intensive care. Blood samples were collected between
March 3 and March 30, 2020.
Serum neopterin, TRP, KYN, and IFN-y measurements
Serum neopterin concentrations were determined using
enzyme-linked immunosorbent assay (ELISA) (BRAHMS
GmbH, Hennigsdorf, Germany) as described by the
manufacturer’s instructions. Serum samples and stan-
dards were treated with Igepal (Sigma-Aldrich, Vienna,
Austria; final concentration in serum or standards was
2% (v/v)). Sensitivity of the test was 2 nmol/L neopterin.
The upper normal reference level was 9.1 nmol/L in
serum [12]. Serum TRP and KYN concentrations were
measured by a reverse-phase HPLC method [13], using a
Varian ProStar HPLC system equipped with a solvent
delivery module (model 210), an autosampler (model
400, both Varian ProStar), an UV-spectrometric detector
(SPD-6A, Shimadzu), and a fluorescence detector (model
360, Varian ProStar). Varian Star Chromatography
Workstation (version 6.30) software was used. To
analyze serum IFN-y, we used the human IFN-gamma
Quantikine ELISA (R&D-DIF50C) according to the
manufacturer’s instructions.
Statistical analyses
Descriptive statistics are shown for all variables involved
in the analyses, presented as means with standard devia-
tions. For statistical analyses, continuous variables were
log10 transformed. Student’s t-test was used for group
comparisons. Changes in log concentrations from first
to last measure were analyzed with paired t-test. Associ-
ations were measured with Pearson correlation. To study
the change in neopterin levels over time, we used a lin-
ear mixed effects model with severity (mild/severe), days
since symptom onset, and age as covariates. An inter-
action term between severity and days since onset was
included in the model. All statistical analyses were
performed with the Statistical Package for the Social Sci-
ences (SPSS) software version 25 (SPSS, Chicago, Illinois,
USA) or Prism (GraphPad software version 8.0, La Jolla,
California, USA). A significance level below 0.05 was
considered as statistically significant.
Results
The study population comprised 34 patients with
COVID-19, of which 15 displayed mild symptoms (mean
age 51.3 years (SD 13.7)), and 19 developed a severe
form of the disease (mean age 61.3 years (SD 11.4)).
Cough, myalgia, nasal congestion, fever, and sore throat
were the most common symptoms among mild cases,
whereas fever, cough, dyspnea, and fatigue were most
frequent in severe cases (Table 1). Among severe cases,
all but four required invasive mechanical ventilation, and
three were in need of continuous renal replacement
therapy. Four deaths occurred in this group. Comorbidi-
ties among mild cases were rare, while a majority of se-
vere cases had one or more comorbidities, of which
hypertension and diabetes mellitus were most frequent
(Table 1).
To test whether neopterin levels are associated with
the severity of COVID-19, we compared serum neop-
terin concentrations between patients with mild and se-
vere disease. We found a more than two-fold higher
mean concentration of neopterin in severely ill patients
(mean value 42.0 nmol/L (SD 18.2)) compared to pa-
tients with mild symptoms (16.9 nmol/L (SD 11.0))
(Table 2, Figs. 1 and 2). All of the severe cases had
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elevated neopterin concentrations (> 9.1 nmol/L) at the
initial sampling with values ranging from 17.2 to 86.7
nmol/L, measured at day 4–20 (mean 11.7 (SD 5.8); me-
dian 14) since onset of symptoms. In comparison, 10 of
15 patients with mild disease had neopterin levels above
9.1 nmol/L at day 2–19 (mean 10.2 (SD 9); median 9),
with concentrations for the entire group in the range
from 4.9 to 31.6 nmol/L. These results show that pa-
tients with severe COVID-19 display higher levels of
neopterin than mild cases. Since renal insufficiency may
affect serum neopterin levels [14], we analyzed creatin-
ine levels in relation to neopterin in severe cases. How-
ever, no significant correlation was found (r = 0.36, p =
0.13). Moreover, we found no association between neop-
terin levels and C-reactive protein (CRP) or B-
lymphocytes among the severely ill (data not shown).
As a next step, we studied the trajectory of neopterin
during the progression of COVID-19 by repeated mea-
surements. We found that serum neopterin levels de-
creased over time, regardless of mild or severe disease
(p < 0.0001, Fig. 3). At day 14 after symptom onset, the
group with severe disease displayed 2.3 times higher
neopterin levels than patients with mild disease. More-
over, neopterin concentrations decreased 23% per week
in severe cases compared to 31% per week in mild cases.
The difference in slope was, however, not significant
(p = 0.23). Twelve of the patients with mild disease had
normal levels (< 9.1 nmol/L) at the last measurement. In
contrast, only one patient among the severely ill
returned to a normal level during the study period (Fig.
3). These results show that neopterin levels gradually de-
crease during the course of COVID-19, but that severe
cases maintain elevated levels for a longer period. Col-
lectively, our findings indicate an association between
neopterin and the severity of COVID-19.
Furthermore, we investigated TRP, KYN, and IFN-y
concentrations in relation to mild and severe COVID-
19. As seen in Fig. 1, we found lower levels of TRP and
higher levels of KYN in severe cases, as compared to
mild cases. This indicates that a severe form of COVID-
19 is associated with an increased TRP catabolism. Add-
itionally, KYN/TRP concentrations closely correlated to
neopterin (r = 0.7, p < 0.0001, Fig. 4). Analysis of IFN-y
in serum revealed significantly higher levels in severe
cases compared to mild cases (Table 2), and the levels of
IFN-y correlated to neopterin (r = 0.8, p < 0.0001).
Discussion
In the present study, we investigated if serum neopterin
levels in patients with COVID-19 are associated with the
severity of disease. We report that higher neopterin con-
centrations were seen in patients who developed severe
disease compared to patients with mild disease. In the
group with severe COVID-19, we also found an in-
creased metabolism of TRP, as expressed by higher KYN
to TRP ratio.
The observed difference in neopterin concentrations
between mild and severe COVID-19 is in agreement
with previous results from SARS patients [3]. In that
study, higher neopterin levels were associated with a lon-
ger fever period, as well as a severer course of disease.
Moreover, a recent report on hospitalized COVID-19
patients showed that neopterin levels were significantly






Gender (M/F) 6/9 17/2
Age, years (SD) 51.3 (13.7) 61.3 (11.4)
Comorbidity, n (%) 2 (13) 11 (58)
Hypertension 0 (0) 11 (58)
Diabetes mellitus 1 (7) 6 (32)
Coronary heart disease 1 (7) 3 (16)
Chronic obstructive
pulmonary disease
0 (0) 1 (5)
Asthma 0 (0) 1 (5)
Symptoms, n (%)
Fever 9 (60) 19 (100)
Cough 14 (93) 18 (95)
Dyspnea 1 (7) 17 (89)
Fatigue 3 (20) 12 (63)
Myalgia 11 (73) 5 (26)
Sore throat 8 (53) 2 (11)
Nasal congestion 11 (73) 1 (5)
Intensive care, n (%) 0 (0) 17 (89)
Invasive mechanical
ventilation, n (%)
0 (0) 15 (79)
Continuous renal
replacement therapy, n (%)
0 (0) 3 (16)
Death, n (%) 0 (0) 4 (21)
M males, F females
Table 2 Concentrations of neopterin and amino acids from the
study population divided into two groups based on disease
severity
Mild (n = 15)
Mean (SD)
Severe (n = 19)
Mean (SD)
p-value
Days since onset 10.2 (9.0) 11.7 (5.8)
Neopterin, nmol/L 16.9 (11.0) 42.0 (18.2) p < 0.0001
Tryptophan, μmol/L 56.3 (11.6) 31.9 (13.0) p < 0.0001
Kynurenine, μmol/L 2.6 (0.7) 4.3 (1.4) p < 0.0001
KYN/TRP *1000 47.5 (15.1) 163.4 (117.5) p < 0.0001
IFN-y, pg/mL 6.7 (5.0) 21.4 (20.8) p < 0.001
Means and standard deviations (SD) are shown
KYN/TRP kynurenine to tryptophan ratio, IFN-y interferon-gamma
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higher in severe cases compared to mild cases [15]. Be-
sides supporting these findings, our study adds the tra-
jectory of neopterin levels with repeated measurements,
where we found that most patients with mild symptoms
returned to normal neopterin levels at the end of the
study period. In contrast, neopterin levels remained
elevated during the course of disease in the severely
ill. This probably illustrates a more advanced and
prolonged inflammatory state, as suggested by others
[16].
The elevated levels of neopterin and IFN-y in severely
ill patients with COVID-19 indicate a potent stimulation
Fig. 1 Concentrations of first measurements of serum neopterin, tryptophan, and kynurenine, as well as kynurenine to tryptophan ratio (K/T) in
patients with mild (green) and severe (red) form of COVID-19 (n = 34). The dashed line represents the upper normal reference limit of neopterin
at 9.1 nmol/L.
Fig. 2 First measurements of serum neopterin concentrations in patients with mild (green) and severe (red) form of COVID-19 (n = 34). The
dashed line represents the upper normal reference limit of neopterin at 9.1 nmol/L.
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of the monocyte/macrophage–T cell interplay during
the symptomatic period [9]. Our detection of high neop-
terin concentrations already at day 2 after symptom on-
set suggests an early inflammatory response to SARS-
CoV-2. Likewise, the study of SARS patients [3], and
also a study of dengue fever [8], found neopterin eleva-
tion at the first day of symptoms. The characteristics of
neopterin being elevated at an early stage of disease, as
well as being associated to disease severity, suggest it as
a useful prognostic marker for COVID-19.
The increased KYN to TRP ratio in patients with se-
vere COVID-19 reflects an increased TRP catabolism.
Similar findings have been presented for HIV-infected
patients with a progressive disease [17]. TRP deprivation
is an effective strategy of the Th1-type immune response
to reduce undesirable proliferation of pathogens and in-
fected cells [18], which may be useful for disease control
in COVID-19.
When interpreting our results, one must consider the
potential involvement of renal function [14]. Acute kid-
ney injury has been found in 50% of fatal COVID-19
cases [19]. In this context, the lack of creatinine mea-
surements in mild cases make out a limitation of the
present study. However, we found no correlation
Fig. 3 Repeated measurements of serum neopterin concentrations in patients with mild (green) and severe (red) form of COVID-19 (n = 34).
Severity (mild/severe), days since symptom onset, and age were used as covariates in the linear mixed effect model. The black dashed line
represents the upper normal reference limit of neopterin at 9.1 nmol/L.
Fig. 4 The correlation between first measurements of serum neopterin (S Neopt) concentration and kynurenine to tryptophan ratio (K/T) in
patients suffering from COVID-19 (n = 34)
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between creatinine and neopterin levels in the severe
cases at the first measurement.
Conclusions
The present study shows an association between neop-
terin levels and severity of COVID-19, and also elevated
concentrations early in disease progression. In conclu-
sion, serum neopterin is a potential marker for the prog-
nosis of COVID-19 when detected in blood samples
from a few days since symptom onset, but further stud-
ies are needed to elucidate how it can be used in the
clinic.
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